Regina Feederle

Title: Regina Feederle: A Pioneer in Cancer Research Innovations

Introduction

Regina Feederle is an accomplished inventor based in Munich, Germany, known for her significant contributions to the field of cancer research. With six patents to her name, she has dedicated her career to developing innovative solutions that address crucial challenges in medicine and metabolic diseases.

Latest Patents

Two of Regina's most notable recent patents illustrate her groundbreaking work. The first is the patent for an improved anti-CD73 monoclonal antibody. This invention focuses on creating antibodies that specifically bind to a membrane-bound form of the CD73 protein, which plays a cancer-promoting role. Importantly, these antibodies inhibit the enzymatic activity of the cancer-associated protein while not affecting the soluble form of CD73 involved in cardioprotection. This dual action offers promising avenues for cancer treatment and diagnostics.

The second patent pertains to a method of using tissue-specific exosomes as biomarkers. This invention provides innovative means for diagnosing, monitoring, and predicting the risk of developing metabolic diseases. By employing exosomes as biomarkers, Regina’s patent lays the foundation for enhanced strategies in bio-medicine, particularly in understanding and managing metabolic health.

Career Highlights

Throughout her career, Regina Feederle has worked at prestigious research institutions, including the German Cancer Research Center (Deutsches Krebsforschungszentrum) and the Helmholtz Center Munich - German Research Center for Environmental Health (Helmholtz Zentrum München). Her research and innovations have significantly impacted the fields of oncology and metabolic disease, establishing her as a leading inventor in these domains.

Collaborations

Regina has collaborated with esteemed colleagues, including Henri-Jacques Delecluse and Emmalene Bartlett, amplifying the potential impact of her work. These collaborations have enriched her research endeavors and facilitated the sharing of expertise, which is essential for pioneering advancements in scientific research.

Conclusion

Regina Feederle's innovative contributions and patents demonstrate her commitment to advancing medical science, particularly in cancer therapy and metabolic disease management. Her work not only showcases the importance of collaboration in research but also exemplifies how targeted inventions can facilitate significant medical breakthroughs. As she continues her groundbreaking work, Regina remains a vital figure in the landscape of scientific innovation.